Form 4: Cognition Therapeutics CFO Reports RSU Grant, Tax Sale

Cognition Therapeutics' CFO, John Brendan Doyle, reported an acquisition of 200,000 restricted stock units and a subsequent disposition of shares for tax obligations.

Summary

• John Brendan Doyle, Chief Financial Officer of Cognition Therapeutics Inc. (CGTX), acquired 200,000 shares of Common Stock on February 3, 2026, in the form of Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement, with an acquisition price of $0.00 per share.
• Following this acquisition, Doyle's beneficial ownership of Common Stock increased to 645,990 shares.
• On February 4, 2026, Doyle disposed of 26,921 shares of Common Stock at a price of $1.03 per share.
• This disposition was explicitly for covering tax withholding obligations related to the vesting of RSUs.
• After the tax-related disposition, Doyle's direct beneficial ownership of Common Stock stands at 619,069 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as the RSU grant aligns management incentives with shareholder interests, while the tax-related sale is a neutral, routine occurrence.

Positives

• The acquisition of 200,000 Restricted Stock Units (RSUs) indicates continued equity-based compensation for the Chief Financial Officer, aligning management's interests with shareholder value.

Negatives

• The disposition of 26,921 shares was solely to cover tax withholding obligations associated with RSU vesting, which is a routine and non-discretionary event, not reflecting a negative outlook on the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) and subsequent sale for tax withholding are standard practices in executive compensation across the biotechnology and pharmaceutical industries. This type of filing primarily serves to disclose changes in insider ownership, which is a regulatory requirement for publicly traded companies.

Stakeholder Impact

• Shareholders: The RSU grant increases the CFO's direct stake in the company, potentially strengthening alignment with shareholder interests. The tax-related sale has a negligible dilutive effect.

Key Dates

Keywords

Cognition Therapeutics, CGTX, Form 4, Insider Transaction, Restricted Stock Units, RSU, Chief Financial Officer, CFO, Equity Compensation, Stock Ownership